TRAW vs. IMMX, LPTX, RPHM, THTX, BLRX, CALC, CARM, RMTI, AEON, and ANEB
Should you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include Immix Biopharma (IMMX), Leap Therapeutics (LPTX), Reneo Pharmaceuticals (RPHM), Theratechnologies (THTX), BioLineRx (BLRX), CalciMedica (CALC), Carisma Therapeutics (CARM), Rockwell Medical (RMTI), AEON Biopharma (AEON), and Anebulo Pharmaceuticals (ANEB). These companies are all part of the "pharmaceutical preparations" industry.
Traws Pharma (NASDAQ:TRAW) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, community ranking, dividends, institutional ownership, analyst recommendations, earnings and valuation.
Immix Biopharma has lower revenue, but higher earnings than Traws Pharma. Immix Biopharma is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Immix Biopharma had 1 more articles in the media than Traws Pharma. MarketBeat recorded 2 mentions for Immix Biopharma and 1 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 1.89 beat Immix Biopharma's score of 1.43 indicating that Traws Pharma is being referred to more favorably in the media.
Immix Biopharma received 4 more outperform votes than Traws Pharma when rated by MarketBeat users.
8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 3.3% of Traws Pharma shares are owned by company insiders. Comparatively, 55.9% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Immix Biopharma has a net margin of 0.00% compared to Traws Pharma's net margin of -8,033.63%. Immix Biopharma's return on equity of -95.00% beat Traws Pharma's return on equity.
Immix Biopharma has a consensus price target of $14.00, indicating a potential upside of 563.51%. Given Immix Biopharma's higher possible upside, analysts clearly believe Immix Biopharma is more favorable than Traws Pharma.
Traws Pharma has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500.
Summary
Immix Biopharma beats Traws Pharma on 9 of the 15 factors compared between the two stocks.
Get Traws Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Traws Pharma Competitors List
Related Companies and Tools
